SCHEMBL19837994

SCHEMBL19837994

Cn1ccc2c1c1c(-c3ccoc3)ncnc1n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 8/20 0.72
▸ DNPH1 O43598 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21351704 1.00 ADK (0.72) ADKDNPH1
SCHEMBL21351701 0.84 ADK (1.00) ADK
SCHEMBL19838018 0.84 ADK (1.00) ADK
SCHEMBL19837990 0.83 ADK (0.70) ADK
SCHEMBL19837980 0.82 ADK (0.72) ADKDNPH1
SCHEMBL19837963 0.82 ADK (0.69) ADK
SCHEMBL19837996 0.82 ADK (0.69) ADK
SCHEMBL21368892 0.81 ADK (0.61) ADKDNPH1
SCHEMBL21351731 0.80 ADK (0.67) ADK
SCHEMBL19837987 0.80 ADK (0.67) ADK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US claimed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP claimed
EP-3494122-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2019-06-12 — — EP claimed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US claimed
WO-2018024265-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2018-02-08 — — WO claimed
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US disclosed
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US disclosed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP disclosed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP disclosed
EP-3494122-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2019-06-12 — — EP disclosed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed
WO-2018024265-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2018-02-08 — — WO disclosed
WO-2018024265-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use DPYD, MTAP, TYMP ADK 664/4885DNPH1 1316/4885
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE DPYD, MTAP, TYMP ADK 664/4885DNPH1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback